<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Isoniazid (INH) poisoning</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Isoniazid (INH) poisoning</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Isoniazid (INH) poisoning</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rama B Rao, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michele M Burns, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michelle Ruha, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Ganetsky, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 17, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">Isoniazid</a> (INH) is an antibiotic used to treat infection with Mycobacterium tuberculosis (TB). A large portion of the world's population is infected with TB. Although the disease is inactive in the majority, up to 10 percent of these persons may become infectious in their lifetime [<a href="#rid1">1-3</a>]. Many patients who are identified as being at risk of developing active, infectious TB or who suffer from active disease are treated with INH.</p><p>Acute INH toxicity frequently manifests as altered mental status or seizures. Poisoning may occur with unintentional ingestion in children, suicidal intent, or in patients taking extra tablets to compensate for missed doses [<a href="#rid4">4-6</a>]. Chronic INH toxicity frequently manifests as peripheral neuropathy or hepatotoxicity, although other chronic conditions are described.</p><p>The presentation and management of acute INH poisoning will be reviewed here. Chronic INH hepatotoxicity and the clinical use of INH are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/477.html" rel="external">"Isoniazid hepatotoxicity"</a> and  <a class="medical medical_review" href="/z/d/html/481.html" rel="external">"Isoniazid: An overview"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PHARMACOLOGY AND CELLULAR TOXICOLOGY</span><span class="headingEndMark"> — </span>The antimicrobial activity of <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">Isoniazid</a> (INH) is selective for mycobacteria, probably resulting from its ability to inhibit mycolic acid synthesis. This inhibition interferes with cell wall synthesis, producing a bactericidal effect. (See  <a class="medical medical_review" href="/z/d/html/481.html" rel="external">"Isoniazid: An overview"</a>.)</p><p>INH toxicity stems from several causes, including deficiencies of pyridoxine (vitamin B6) and gamma amino butyric acid (GABA). INH induces a state of functional pyridoxine deficiency by at least two mechanisms. First, INH metabolites directly attach to and inactivate pyridoxine species. Second, INH inhibits the enzyme pyridoxine phosphokinase; this enzyme is necessary to activate pyridoxine to pyridoxal 5' phosphate, the cofactor in many "pyridoxine-dependent" reactions. Functional pyridoxine deficiency is the likely mechanism of INH-induced peripheral neuropathy.</p><p>INH may induce a critical deficiency in GABA, an inhibitory neurotransmitter that modifies or suppresses excitatory neurons [<a href="#rid7">7,8</a>]. GABA is produced in a pyridoxine-dependent decarboxylation reaction. The functional pyridoxine deficiency induced by INH leads to a reduction in GABA production. In addition, INH inhibits glutamate dehydrogenase, the enzyme which catalyzes the conversion of glutamate to GABA. GABA deficiency may manifest as seizures, particularly in acute overdose.</p><p>INH metabolites, such as acetylhydrazine, cause idiosyncratic direct hepatocellular toxicity. The mechanisms of chronic INH hepatotoxicity are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/477.html" rel="external">"Isoniazid hepatotoxicity", section on 'Mechanism of hepatotoxicity'</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">KINETICS</span><span class="headingEndMark"> — </span>INH is rapidly absorbed from the gastrointestinal tract. Its volume of distribution is between 0.6 and 1.2 L/kg. INH undergoes hepatic metabolism to hydrazones, as well as acetylation to hydrazine and hydrazides. The rate of acetylation may vary by population and affects the elimination half-life. INH may inhibit hepatic enzymes CYP2C9, 2C19, 3A4, and 2E1. The major route of elimination is via the kidney. The pharmacokinetics of INH are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/481.html" rel="external">"Isoniazid: An overview", section on 'Pharmacokinetics'</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL FEATURES OF ACUTE TOXICITY</span><span class="headingEndMark"> — </span>Acute INH overdose usually manifests as altered or depressed mental status or seizures, including status epilepticus [<a href="#rid9">9</a>]. Higher ingestion doses (≥20 mg/kg) increase the likelihood of seizures [<a href="#rid7">7</a>]. An acute ingestion of 2 g may cause toxicity in some adults [<a href="#rid8">8</a>].</p><p>Clinically, seizures may be discrete and isolated, or in severe overdoses, present as status epilepticus. Seizures most commonly start within 30 minutes of the exposure, but may begin up to two hours later and persist for many hours. The patient may also have an altered or depressed mental status in the absence of seizure activity [<a href="#rid6">6,10-13</a>]. Co-ingestants may alter the time of onset or duration of toxicity.</p><p>Vital sign abnormalities such as tachycardia, tachypnea, and elevations in temperature may occur as a result of seizure activity. Anoxia and aspiration are potential complications. Long-term sequelae include anoxic encephalopathy and dementia [<a href="#rid14">14</a>]. The management of INH-induced seizures is described below. (See <a class="local">'Seizure management'</a> below.)</p><p class="headingAnchor" id="H5"><span class="h1">CLINICAL FEATURES OF CHRONIC TOXICITY</span></p><p class="headingAnchor" id="H6"><span class="h2">Hepatotoxicity</span><span class="headingEndMark"> — </span>Chronic hepatotoxicity from INH can develop within the first eight weeks of therapy but may develop months later. INH-induced hepatotoxicity is defined as an AST elevation of three times the upper limit of normal in a patient with symptoms including nausea, vomiting, abdominal pain, or jaundice, or an AST elevation five times the upper limit of normal in an asymptomatic patient. The diagnosis, management, and monitoring of chronic INH hepatotoxicity are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/477.html" rel="external">"Isoniazid hepatotoxicity"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Peripheral neuropathy</span><span class="headingEndMark"> — </span>A sensory peripheral neuropathy can occur in patients taking INH and may be prevented by administering supplemental pyridoxine. Often, patients complain of bilateral numbness and tingling or burning of upper and lower extremities.</p><p>Rarely, INH-induced neuropathy may include central features such as ataxia and nystagmus [<a href="#rid15">15</a>]. Other reactions to INH therapy have been reported and are listed in the attached table  (<a class="graphic graphic_table graphicRef75525" href="/z/d/graphic/75525.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H8"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Patients without a clear history of INH exposure who present with seizures should undergo a comprehensive evaluation for non-toxicologic causes (see  <a class="medical medical_review" href="/z/d/html/2219.html" rel="external">"Evaluation and management of the first seizure in adults"</a>). If a toxic ingestion is suspected, other (non-INH) causes of seizures should also be entertained  (<a class="graphic graphic_table graphicRef83223" href="/z/d/graphic/83223.html" rel="external">table 2</a>).</p><p>No focal findings distinguish INH-induced status epilepticus from other types of prolonged seizures. The key difference is that seizures due to INH poisoning are often refractory to treatment with benzodiazepines and are difficult to manage without pyridoxine. (See <a class="local">'Seizure management'</a> below.)</p><p>Clinicians should suspect INH as a possible cause of seizures when the patient or a patient's family member is being treated with INH or has emigrated from an area where tuberculosis infection is endemic.</p><p class="headingAnchor" id="H9"><span class="h1">LABORATORY EVALUATION</span><span class="headingEndMark"> — </span>Metabolic abnormalities in acute INH toxicity relate directly to seizure activity and may include metabolic acidosis (due to lactate production), an elevated creatine kinase, and (later) renal insufficiency from rhabdomyolysis [<a href="#rid4">4</a>]. Therefore, laboratory evaluation should include a basic metabolic profile, serum lactate, liver enzymes, blood gas (to assess acid/base and ventilatory status), and creatine kinase, as well as a pregnancy test in women of childbearing age. INH concentrations are not clinically useful as results may take days or weeks to perform.</p><p>Additional tests for patients with an intentional overdose also include:</p><p class="bulletIndent1"><span class="glyph">●</span>Fingerstick glucose, to rule out hypoglycemia as the cause of any seizure or alteration in mental status</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">Acetaminophen</a> and salicylate testing to rule out these common co-ingestants</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An electrocardiogram to rule out conduction system poisoning by drugs that effect the QRS or QTc intervals</p><p></p><p class="headingAnchor" id="H10"><span class="h1">MANAGEMENT OF ACUTE TOXICITY</span></p><p class="headingAnchor" id="H11"><span class="h2">Airway management</span><span class="headingEndMark"> — </span>The clinician should be prepared to establish a definitive airway with tracheal tube for patients with coma, seizures, or status epilepticus. Patients with a clinically severe INH overdose are at high risk for aspiration and prolonged hypoxia. Airway management is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/270.html" rel="external">"Rapid sequence intubation in adults for emergency medicine and critical care"</a> and  <a class="medical medical_review" href="/z/d/html/276.html" rel="external">"Overview of advanced airway management in adults for emergency medicine and critical care"</a> and  <a class="medical medical_review" href="/z/d/html/6390.html" rel="external">"Rapid sequence intubation (RSI) in children for emergency medicine: Approach"</a> and  <a class="medical medical_review" href="/z/d/html/6316.html" rel="external">"Technique of emergency endotracheal intubation in children"</a>.)</p><p>If a neuromuscular blocking agent (NMBA) is used for tracheal intubation, a short-acting drug such as <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">succinylcholine</a> is preferred. Longer-acting agents may mask seizure activity and should be avoided if possible, unless monitoring with an electroencephalogram (EEG) is performed. If use of a longer-acting NMBA is required, then ensure adequate pharmacological sedation is provided.</p><p>During any period of drug-induced paralysis, pupillary response may help to determine the presence of an active seizure. Pupillary reactivity is not typically affected by nicotinic neuromuscular antagonists (eg, <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">succinylcholine</a>). Nonreactive pupils suggest active seizures and require therapy with pyridoxine as well as GABA agonist medications, such as benzodiazepines. (See <a class="local">'Seizure management'</a> below.)</p><p class="headingAnchor" id="H12"><span class="h2">Gastrointestinal decontamination</span><span class="headingEndMark"> — </span>There are limited data regarding the role of activated charcoal (AC) or gastric lavage in INH poisoning. While INH is readily bound by AC, the drug is absorbed rapidly and patients with INH overdose are at high risk for aspiration. Thus, we give AC (1 g/kg by mouth or by nasogastric or orogastric tube) only to patients who present early (within one to two hours) following an acute ingestion. AC should be withheld in patients who are sedated and may not be able to protect their airway, unless the patient is intubated. However, tracheal intubation should not be performed solely for the purpose of giving AC.</p><p>Gastric lavage is rarely indicated. Patients with evidence of severe toxicity (eg, status epilepticus) who present within one to two hours of ingestion and who are either protecting their airway (uncommon with severe toxicity) or have undergone tracheal intubation are candidates for gastric lavage. However, AC is likely to prevent greater absorption unless the overdose is massive. (See  <a class="medical medical_review" href="/z/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient", section on 'Gastric lavage'</a>.)</p><p>Whole bowel irrigation is unlikely to empty the bowels prior to the onset of central nervous system toxicity and is <strong>not</strong> recommended. Syrup of ipecac should be avoided, even in the otherwise asymptomatic patient, since seizures may begin during the induction of emesis, increasing the risk of aspiration.</p><p class="headingAnchor" id="H13"><span class="h2">Seizure management</span><span class="headingEndMark"> — </span>The goal of seizure management in acute INH poisoning is to repair the critical deficiency in the inhibitory neurotransmitter gamma amino butyric acid (GABA). This is accomplished by intravenous (IV) administration of <strong>both</strong> pyridoxine (to overcome functional pyridoxine deficiency) and a benzodiazepine (eg, <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a>), which potentiates the effects of available GABA [<a href="#rid7">7,8,10,16</a>]. The use of either agent alone may be inadequate to control seizure activity.</p><p class="headingAnchor" id="H14"><span class="h3">Pyridoxine</span><span class="headingEndMark"> — </span>Pyridoxine (vitamin B6) binds to INH, replaces stores of pyridoxine and pyridoxal 5' phosphate, and facilitates the production of GABA [<a href="#rid7">7,10,11</a>]. The onset of action is rapid. Patients in status epilepticus refractory to benzodiazepines often stop seizing within minutes of pyridoxine administration. (See <a class="local">'Pharmacology and cellular toxicology'</a> above.)</p><p>The dose of pyridoxine is 1 g intravenously for every gram of INH ingested [<a href="#rid9">9</a>]. When the quantity of INH ingested is unknown, 5 g IV may be administered to an adult and 70 mg/kg (maximum 5 g) to a child. The dose can be administered at a rate of 0.5 g/min, and may be repeated in patients with refractory seizure activity [<a href="#rid7">7,8,17,18</a>].</p><p>Pyridoxine is a water-soluble vitamin with a wide therapeutic margin. Acute pyridoxine-induced neuropathy is reported at doses of 1 g/kg, a dose unlikely to be required for the management of INH overdose [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H15"><span class="h3">Benzodiazepines</span><span class="headingEndMark"> — </span>Benzodiazepines act on the GABA receptor and enhance neuroinhibition. <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">Lorazepam</a> may be used to terminate seizure activity from INH poisoning, but may need to be administered repeatedly in escalating doses. In adults with status epilepticus, lorazepam 4 mg IV can be given every five minutes until seizures are controlled. The dose may be doubled in cases of persistent seizures. Alternative benzodiazepines may be used if lorazepam is unavailable. Patients requiring more than 3 doses of lorazepam should be monitored closely, as respiratory depression may ensue even after seizures are controlled. (See  <a class="medical medical_review" href="/z/d/html/96933.html" rel="external">"Convulsive status epilepticus in adults: Management", section on 'First therapy: Benzodiazepines'</a>.)</p><p class="headingAnchor" id="H16"><span class="h3">Other sedative hypnotic medications</span><span class="headingEndMark"> — </span>Ultra-short acting barbiturates are useful for intubation and terminating status epilepticus, but these agents do not have a sustained duration of action for controlling seizures. In addition, they can cause hypotension and should be avoided in hypotensive or hypovolemic patients.</p><p><a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">Phenobarbital</a>, a longer acting barbiturate, may be used as adjunctive therapy for patients with persistent seizures or when there is a delay in obtaining pyridoxine. The dose is 20 mg/kg by slow IV push. Tracheal intubation is usually required when phenobarbital is combined with other sedative-hypnotic agents. Despite its efficacy, phenobarbital is generally not used as a first-line treatment because it is slow to administer. (See  <a class="medical medical_review" href="/z/d/html/96933.html" rel="external">"Convulsive status epilepticus in adults: Management", section on 'Second- or third-line medications'</a>.)</p><p class="headingAnchor" id="H17"><span class="h3">Phenytoin and fosphenytoin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">Phenytoin</a> and <a class="drug drug_general" data-topicid="8480" href="/z/d/drug information/8480.html" rel="external">fosphenytoin</a> are unlikely to be efficacious in treating INH-induced seizures and status epilepticus and are not indicated.</p><p class="headingAnchor" id="H18"><span class="h2">Metabolic acidosis</span><span class="headingEndMark"> — </span>Nearly all the metabolic derangements associated with severe INH toxicity are the result of status epilepticus or refractory seizure activity, which can be associated with lactic acidosis [<a href="#rid7">7</a>]. Stopping the seizure activity and providing adequate ventilatory support usually results in rapid reversal of acidemia, since metabolism of the excess lactate regenerates bicarbonate.</p><p>The appropriate role of <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">sodium bicarbonate</a> administration in INH toxicity remains unclear. Sodium bicarbonate has been used in severe cases of lactic acidosis from status epilepticus [<a href="#rid19">19</a>]. In general, most physicians would limit the use of sodium bicarbonate to patients with severe metabolic acidemia (arterial pH below 7.10 to 7.15) who are otherwise ventilating adequately, with the aim being to maintain the pH above 7.15 until the primary process can be reversed. The administration of sodium bicarbonate should <strong>not</strong> precede treatment with a benzodiazepine and pyridoxine, as the cause of the acidosis will persist despite attempts to correct the pH. (See  <a class="medical medical_review" href="/z/d/html/2294.html" rel="external">"Bicarbonate therapy in lactic acidosis"</a>.)</p><p class="headingAnchor" id="H19"><span class="h2">Enhanced elimination</span><span class="headingEndMark"> — </span>Hemodialysis is generally not indicated in INH poisoning. While hemodialysis may remove INH from the circulation, patients with severe toxicity become symptomatic before it is feasible to perform the procedure. Adequate pyridoxine and benzodiazepine therapy generally obviate the need for hemodialysis [<a href="#rid7">7</a>]. Hemodialysis may be helpful in the rare setting of a massive overdose when adequate pyridoxine is unavailable [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H20"><span class="h2">Prolonged coma</span><span class="headingEndMark"> — </span>Patients with adequate seizure control may develop a persistent coma from INH toxicity or the administration of sedative hypnotic agents. There are reports of supplemental pyridoxine being used to reverse prolonged comas lasting up to 42 hours [<a href="#rid11">11</a>]. The mechanism by which pyridoxine causes such a reversal, remains unclear. Pyridoxine doses of 3 to 5 g in adults (in addition to the initial doses used to treat seizures) were used in these cases. We suggest obtaining consultation with a medical toxicologist or through a poison control center when such treatment is considered. (See <a class="local">'Additional resources'</a> below.)</p><p>Other causes of persistent coma, such as a closed head injury sustained during seizure activity, hypoglycemia, or co-ingestants, should be considered simultaneously when considering treatment with additional pyridoxine. Once a patient regains consciousness from a prolonged coma, they should be assessed for injuries associated with the initial seizure. Spinal compression fractures are among the injuries that have been reported [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/z/d/html/5104.html" rel="external">"Stupor and coma in adults"</a>.)</p><p class="headingAnchor" id="H21"><span class="h2">Hyperthermia</span><span class="headingEndMark"> — </span>Hyperthermia is generally the result of seizure activity and should spontaneously resolve once seizures are controlled. Antipyretics are unnecessary. Causes other than seizure (eg, aspiration pneumonia) should be investigated in patients with a delayed presentation of hyperthermia.</p><p class="headingAnchor" id="H22"><span class="h1">PEDIATRIC CONSIDERATIONS</span><span class="headingEndMark"> — </span>The management of INH overdose is fundamentally the same in children and adults with the exception of medication dosing. Therapeutic dosing for children with INH induced seizures is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">Lorazepam</a> – 0.05 to 0.1 mg/kg intravenously (IV) up to a maximum of 4 mg; the dose may be repeated after five minutes, but the risk of respiratory depression increases after administration of more than two doses of benzodiazepines  (<a class="graphic graphic_table graphicRef55368" href="/z/d/graphic/55368.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/z/d/html/6192.html" rel="external">"Management of convulsive status epilepticus in children", section on 'First therapy: Benzodiazepines'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pyridoxine – 70 mg/kg IV, up to 5 g in a child, with supplemental dosing if this is ineffective. A dose of 1 gram pyridoxine per gram of INH ingested can be used (and may be necessary) if the quantity of INH ingested is known [<a href="#rid21">21</a>].</p><p></p><p>Serum INH concentrations are not typically indicated for clinical management but may be used with infant ingestions to confirm the etiology of seizures after the patient recovers [<a href="#rid12">12</a>].</p><p>When intravenous access is delayed, as may be the case in infants and toddlers, rectal <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">diazepam</a> may be administered. The dose in younger children is 0.5 mg/kg. Intraosseous access is a viable alternative when IV access cannot be obtained (see  <a class="medical medical_review" href="/z/d/html/6321.html" rel="external">"Intraosseous infusion"</a>). Oral pyridoxine per nasogastric tube may be used initially (provided the airway is secure), but IV pyridoxine should be administered as soon as IV access is established.</p><p>On occasion, a child is brought for evaluation after a reported exposure to INH but neither seizures nor altered mental status is observed. In such cases, the child should be observed for six hours to ensure that no signs of toxicity develop and then may be discharged with a responsible adult. </p><p>The circumstance of any possible pediatric exposure should be carefully evaluated to ensure that the safety of the child (and other children who live where the exposure occurred) is adequately addressed. A child prescribed INH who presents with seizures should have their prescription bottles carefully inspected for dosing errors.</p><p class="headingAnchor" id="H24"><span class="h1">DISPOSITION</span><span class="headingEndMark"> — </span>Patients with unintentional exposures who remain asymptomatic with normal vital signs for six hours are unlikely to manifest delayed toxicity and may be medically cleared for discharge.</p><p>Patients with a suicidal overdose who present with seizures should be admitted to an intensive care unit for treatment and observation.</p><p>Patients who are symptomatic from taking extra doses of INH, with the intent of compensating for missed doses, may require admission. The clinician may use discretion if the patient had one seizure that responds to dose-appropriate treatment and then returns to baseline function. Such a patient may be a candidate for discharge if the following conditions are met over a six hour observation period:</p><p class="bulletIndent1"><span class="glyph">●</span>The history of an isolated, accidental overdose is verified.</p><p class="bulletIndent1"><span class="glyph">●</span>The patient remains hemodynamically stable.</p><p class="bulletIndent1"><span class="glyph">●</span>The patient remains free of any seizure activity or alterations in mental status, and maintains a normal level of function.</p><p class="bulletIndent1"><span class="glyph">●</span>There is no concern for occult self-harm</p><p></p><p>However, should the clinician harbor any doubts about the patient's medical condition or whether there is adequate assistance at home, the patient should be admitted for observation.</p><p class="headingAnchor" id="H11187531"><span class="h1">ADDITIONAL RESOURCES</span></p><p class="headingAnchor" id="H2040939274"><span class="h2">Regional poison control centers</span><span class="headingEndMark"> — </span>Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/138307.html" rel="external">"Society guideline links: Regional poison control centers"</a>.)</p><p class="headingAnchor" id="H3358829232"><span class="h2">Society guideline links</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112689.html" rel="external">"Society guideline links: General measures for acute poisoning treatment"</a>.)</p><p class="headingAnchor" id="H25"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacology and cellular toxicology</strong> – <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">Isoniazid</a> (INH) is an antibiotic widely used to treat infection with Mycobacterium tuberculosis (TB). INH toxicity stems from several causes, including deficiencies of pyridoxine (vitamin B6) and gamma amino butyric acid (GABA). INH is rapidly absorbed from the gastrointestinal tract. (See <a class="local">'Pharmacology and cellular toxicology'</a> above and <a class="local">'Kinetics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Acute INH overdose usually manifests as altered or depressed mental status or seizures, including status epilepticus. Seizures may be discrete and isolated, or in severe overdoses, present as status epilepticus. Seizures most commonly start within 30 minutes of the exposure but may begin up to two hours later and persist for many hours. Seizures typically do not respond to standard therapy. (See <a class="local">'Clinical features of acute toxicity'</a> above.)</p><p></p><p class="bulletIndent1">Hepatotoxicity and peripheral neuropathy are potential chronic effects of INH treatment. (See <a class="local">'Clinical features of chronic toxicity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – Patients without a clear history of INH exposure who present with seizures should undergo a comprehensive evaluation for non-toxicologic causes. Clinicians should suspect INH as a possible cause of seizures when the patient or a patient's family member is being treated with INH or has emigrated from an area where tuberculosis infection is endemic, or when seizures fail to respond to appropriate benzodiazepine therapy. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory evaluation</strong> – Metabolic abnormalities in acute INH toxicity relate directly to seizure activity. Laboratory evaluation should include a basic metabolic profile, serum lactate, liver enzymes, blood gas, and creatine kinase, as well as a pregnancy test in women of childbearing age. INH concentrations are not clinically useful. Standard testing for co-ingestants should be performed. (See <a class="local">'Laboratory evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of acute toxicity</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Airway management</strong> – The clinician should be prepared to establish a definitive airway for patients with coma, seizures, or status epilepticus. Patients with a clinically severe INH overdose are at high risk for aspiration and prolonged hypoxia. (See <a class="local">'Airway management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gastrointestinal decontamination</strong> – We administer activated charcoal (AC) (1 g/kg by mouth or by nasogastric or orogastric tube) only to patients who present early (within one to two hours) following an acute ingestion. AC should be withheld in patients who are sedated and may not be able to protect their airway, unless the patient undergoes tracheal intubation. However, tracheal intubation should not be performed solely for the purpose of giving AC. (See <a class="local">'Gastrointestinal decontamination'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Seizure treatment with pyridoxine and benzodiazepine</strong> – In a patient with a seizure from acute INH poisoning, we recommend treatment with pyridoxine in addition to standard seizure treatment with a benzodiazepine (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). The use of either agent alone may be inadequate to control seizure activity. (See <a class="local">'Seizure management'</a> above.)</p><p></p><p class="bulletIndent2">The dose of pyridoxine is 1 g IV for every gram of INH ingested. When the quantity of INH ingested is unknown, 5 g IV may be administered to an adult and 70 mg/kg (maximum 5 g) to a child. Additional pyridoxine may be needed. (See <a class="local">'Pyridoxine'</a> above and <a class="local">'Pediatric considerations'</a> above.)</p><p></p><p class="bulletIndent2">In adults with status epilepticus, <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a> 4 mg IV can be given every five minutes until seizures are controlled. In children, lorazepam (0.05 to 0.1 mg/kg IV, up to 4 mg per dose) may be given and repeated after five minutes  (<a class="graphic graphic_table graphicRef55368" href="/z/d/graphic/55368.html" rel="external">table 3</a>). Alternative benzodiazepines may be used if lorazepam is unavailable. (See <a class="local">'Benzodiazepines'</a> above and <a class="local">'Pediatric considerations'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">World Health Organization. Tuberculosis. https://www.who.int/news-room/fact-sheets/detail/tuberculosis (Accessed on March 14, 2023).</li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Trends in tuberculosis--United States, 2008. MMWR Morb Mortal Wkly Rep 2009; 58:249.</a></li><li><a class="nounderline abstract_t">Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016; 63:e147.</a></li><li><a class="nounderline abstract_t">Panganiban LR, Makalinao IR, Corte-Maramba NP. Rhabdomyolysis in isoniazid poisoning. J Toxicol Clin Toxicol 2001; 39:143.</a></li><li><a class="nounderline abstract_t">Wilcox WD, Hacker YE, Geller RJ. Acute isoniazid overdose in a compliant adolescent patient. Clin Pediatr (Phila) 1996; 35:213.</a></li><li><a class="nounderline abstract_t">Sullivan EA, Geoffroy P, Weisman R, et al. Isoniazid poisonings in New York City. J Emerg Med 1998; 16:57.</a></li><li><a class="nounderline abstract_t">Lheureux P, Penaloza A, Gris M. Pyridoxine in clinical toxicology: a review. Eur J Emerg Med 2005; 12:78.</a></li><li class="breakAll">Howland MA. Pyridoxine. In: Goldfrank's Toxicologic Emergencies, 11e, Nelson LS, Howland MA, Lewin NA, Smith SW, Goldfrank LR, Hoffman RS (Eds), McGraw Hill, New York, NY 2019. p.862.</li><li><a class="nounderline abstract_t">Glatstein M, Carbell G, Scolnik D, et al. Pyridoxine for the treatment of isoniazid-induced seizures in intentional ingestions: The experience of a national poison center. Am J Emerg Med 2018; 36:1775.</a></li><li><a class="nounderline abstract_t">de' Clari F. The paradoxical anticonvulsive and awakening effect of high-dose pyridoxine treatment for isoniazid intoxication. Arch Intern Med 1992; 152:2346.</a></li><li><a class="nounderline abstract_t">Brent J, Vo N, Kulig K, Rumack BH. Reversal of prolonged isoniazid-induced coma by pyridoxine. Arch Intern Med 1990; 150:1751.</a></li><li><a class="nounderline abstract_t">Shah BR, Santucci K, Sinert R, Steiner P. Acute isoniazid neurotoxicity in an urban hospital. Pediatrics 1995; 95:700.</a></li><li><a class="nounderline abstract_t">Ehsan T, Malkoff MD. Acute isoniazid poisoning simulating meningoencephalitis. Neurology 1995; 45:1627.</a></li><li><a class="nounderline abstract_t">McLay RN, Drake A, Rayner T. Persisting dementia after isoniazid overdose. J Neuropsychiatry Clin Neurosci 2005; 17:256.</a></li><li><a class="nounderline abstract_t">Lewin PK, McGreal D. Isoniazid toxicity with cerebellar ataxia in a child. CMAJ 1993; 148:49.</a></li><li><a class="nounderline abstract_t">Chin L, Sievers ML, Herrier RN, Picchioni AL. Potentiation of pyridoxine by depressants and anticonvulsants in the treatment of acute isoniazid intoxication in dogs. Toxicol Appl Pharmacol 1981; 58:504.</a></li><li><a class="nounderline abstract_t">Morrow LE, Wear RE, Schuller D, Malesker M. Acute isoniazid toxicity and the need for adequate pyridoxine supplies. Pharmacotherapy 2006; 26:1529.</a></li><li><a class="nounderline abstract_t">Burda AM, Sigg T, Haque D, Bardsley CH. Inadequate pyridoxine stock and its effect on patient outcome. Am J Ther 2007; 14:262.</a></li><li><a class="nounderline abstract_t">Black LE, Ros SP. Complete recovery from severe metabolic acidosis associated with isoniazid poisoning in a young boy. Pediatr Emerg Care 1989; 5:257.</a></li><li><a class="nounderline abstract_t">Kalaci A, Duru M, Karazincir S, et al. Thoracic spine compression fracture during isoniazid-induced seizures: case report. Pediatr Emerg Care 2008; 24:842.</a></li><li><a class="nounderline abstract_t">Minns AB, Ghafouri N, Clark RF. Isoniazid-induced status epilepticus in a pediatric patient after inadequate pyridoxine therapy. Pediatr Emerg Care 2010; 26:380.</a></li></ol></div><div id="topicVersionRevision">Topic 316 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.who.int/news-room/fact-sheets/detail/tuberculosis" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : World Health Organization. Tuberculosis. https://www.who.int/news-room/fact-sheets/detail/tuberculosis (Accessed on March 14, 2023).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19300406" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Trends in tuberculosis--United States, 2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27516382" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11407500" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Rhabdomyolysis in isoniazid poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8665756" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Acute isoniazid overdose in a compliant adolescent patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9472761" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Isoniazid poisonings in New York City.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15756083" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Pyridoxine in clinical toxicology: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15756083" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pyridoxine in clinical toxicology: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29397257" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Pyridoxine for the treatment of isoniazid-induced seizures in intentional ingestions: The experience of a national poison center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1290558" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The paradoxical anticonvulsive and awakening effect of high-dose pyridoxine treatment for isoniazid intoxication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2152443" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Reversal of prolonged isoniazid-induced coma by pyridoxine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7724306" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Acute isoniazid neurotoxicity in an urban hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7644069" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Acute isoniazid poisoning simulating meningoencephalitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15939987" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Persisting dementia after isoniazid overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8439890" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Isoniazid toxicity with cerebellar ataxia in a child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7245217" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Potentiation of pyridoxine by depressants and anticonvulsants in the treatment of acute isoniazid intoxication in dogs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16999664" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Acute isoniazid toxicity and the need for adequate pyridoxine supplies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17515701" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Inadequate pyridoxine stock and its effect on patient outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2602206" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Complete recovery from severe metabolic acidosis associated with isoniazid poisoning in a young boy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19092563" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Thoracic spine compression fracture during isoniazid-induced seizures: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20453796" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Isoniazid-induced status epilepticus in a pediatric patient after inadequate pyridoxine therapy.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
